Login / Signup

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease.

Peter C TaylorAyman AskariErnest H S ChoyMichael R EhrensteinSara ElseMuhammad K Nisar
Published in: BMC medicine (2023)
While challenges exist in education and identifying patients who may benefit from the use of biologics, the NICE TA715 recommendations hold great potential in addressing an unmet need for the treatment of moderate RA.
Keyphrases
  • rheumatoid arthritis
  • healthcare
  • quality improvement
  • disease activity
  • clinical practice
  • risk assessment
  • human health
  • interstitial lung disease
  • systemic sclerosis
  • idiopathic pulmonary fibrosis